Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | CCR8 | P51685 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.32 |
| ▸ | NOS2 | P35228 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24004102 | 0.80 | HTR2A (0.33) | HTR2AHTR2CHTR2B | |
| SCHEMBL23856867 | 0.77 | ADRA1A (0.38) | CCR1CCR5CCR8NOS3NOS2 | |
| SCHEMBL30047426 | 0.77 | ADRA1A (0.38) | CCR1CCR5CCR8NOS3NOS2 | |
| SCHEMBL23857683 | 0.77 | CCR1 (0.31) | CCR1CCR5CCR8 | |
| SCHEMBL30047588 | 0.77 | CCR1 (0.31) | CCR1CCR5CCR8 | |
| SCHEMBL29203133 | 0.73 | CCR1 (0.31) | CCR1CCR5CCR8NOS3NOS2 | |
| SCHEMBL23857292 | 0.72 | MAPT (0.34) | — | |
| SCHEMBL30047485 | 0.72 | MAPT (0.34) | — | |
| Hydrochloric Acid SCHEMBL23857003 | 0.70 | MAPT (0.33) | — | |
| Hydrochloric Acid SCHEMBL23856490 | 0.70 | MAPT (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135534-A1 | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR-GAMMA AND OTHER USES | REATA PHARMACEUTICALS, INC. (US) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135534-A1 | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR-GAMMA AND OTHER USES | RORC, RORB, RORA | CCR1 152/4885CCR5 147/4885CCR8 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.